Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: An adverse event (AE)-based analysis.

• DOI: 10.1200/jco.2024.42.16_suppl.e19049
• Publication Date: 2024-07-02T01:50:31Z
• Authors: Tahla Munir; Yucai Wang; Leyla Mohseninejad; Tushar Srivastava; Anurag Gupta; Raju Gautam; Swetha Challagulla; Mei Xue; Keri Yang; Rhys Williams; Vincent Levy; Shouhao Zhou
• Keywords: 03 medical and health sciences; 0302 clinical medicine

e19049 Background: Acala and zanu are 2 nd generation Bruton tyrosine kinase inhibitors (BTKis) that have demonstrated improved safety profiles vs 1 st BTKi ibrutinib in clinical trials. While head-to-head comparison of acala is lacking, a recent meta-analysis trials provided comprehensive, indirect the AE B-cell malignancies (Hwang, Hemasphere. 2023;7(S3):1134). This study aims to evaluate costs impacts on quality life (QoL) for using their profiles. Methods: A health economic model was developed determine cost QoL associated with management acala. The incidence rates ( IRs) all grade ≥3 AEs interest (n=21, including bleeding events, hypertension, atrial fibrillation, cytopenias, infections, headache, arthralgia, diarrhea) were taken from meta-analysis. Additional inputs, such as disutility, average duration AE, unit each sourced published literature publicly available databases consultation experts. US perspective, considering Medicare costs, inflated 2023 USD. Model outcomes (= IR * cost) quality-adjusted years (QALYs) lost due Disutility Duration/365.25). Results: In base-case scenario (considering AEs), treating hypothetical cohort 1000 patients (pts) instead yielded savings $124K 3.7 QALY gains (i.e., extra full health). Subgroup analysis severe (grade ≥3) non-severe 1-2) similar trends. sensitivity limited significantly different between (n=13) consistent results. Additionally, probabilistic analysis, conducted iterations account uncertainty parameters, confirmed robustness model, indicating stable conclusions across wide range parameter uncertainties. Conclusions: suggested cost-saving added benefits compared terms pts malignancies. Should these results derived trial data be applicable real-world pt populations indications, potential could considerable. These further if differences efficacy also incorporated. [Table: see text]